Metraipolis › archive › dc_006a6f2bdf52
Case Report: Dupilumab therapy for immune checkpoint inhibitor-induced bullous pemphigoid enables dual immunotherapy initiation in progressive malignant… — Europe PMC PMID:41079106
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41079106
- DOI
- 10.3389/fonc.2025.1613552
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T18:23:59.394Z
- SHA-256 of the archived text
00755797eed8cce1adff7efce202f872f2773f7788bfb9dcc02a40bde0f3c4de- Stable URL of this page
https://metraipolis.com/documento/dc_006a6f2bdf52
How to cite
Case Report: Dupilumab therapy for immune checkpoint inhibitor-induced bullous pemphigoid enables dual immunotherapy initiation in progressive malignant… — Europe PMC PMID:41079106 — Europe PMC (en), https://europepmc.org/article/MED/41079106 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_006a6f2bdf52 (Metraipolis archive dc_006a6f2bdf52, sha256 00755797eed8cce1adff7efce202f872f2773f7788bfb9dcc02a40bde0f3c4de)
BibTeX
@misc{dc006a6f2bdf52,
title = {Case Report: Dupilumab therapy for immune checkpoint inhibitor-induced bullous pemphigoid enables dual immunotherapy initiation in progressive malignant… — Europe PMC PMID:41079106},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41079106},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_006a6f2bdf52; sha256 00755797eed8cce1adff7efce202f872f2773f7788bfb9dcc02a40bde0f3c4de},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41079106. Agents can read the archived copy with the MCP tool read_document.